Value-Based Oncology Benefit Design™ Balancing Cost, Quality, and Access in Cancer Care

Supplements
Download PDF
Gary M. Owens, MD
Al B. Benson III, MD, FACP
Gary Rice, RPh, MS, MBA

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: June 30th, 2009 - June 30th, 2010

This activity is no longer available for credit, however its content is still relevant for your educational needs.

Target Audience
This activity was developed for pharmacists and other healthcare professionals practicing in a managed care environment who wish to enhance their knowledge concerning the implementation of a value-based benefit design for cancer care.

Learning Objectives
At the completion of this activity participants should be able to:

  • Identify the intersection of epidemiologic shifts in the American cancer patient population.
  • Identify new cancer drug costs and define the role of value (cost, quality, access) in the new value-based healthcare system, as well as the incentives of payers and purchasers to meet each of these 3 aspects of value in cancer care.
  • Define how new diagnostic measures may help determine how to better achieve value-based clinical cancer treatment outcomes and determine how clinical practice treatment guidelines are aiding all stakeholders in attaining value-based cancer care amidst rising new product costs.


Disclosure Statement
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

The associates of Medical Learning Institute, Inc. have no financial relationships to disclose. The associates of Center of Excellence Media, LLC, have no financial relationships to disclose.

Faculty Disclosures
Gary M. Owens, MD, is a Consultant to Asthmatx, Biosense Webster, Centocor-OrthoBiotech, Eli Lilly, Genentech, and Novartis.

Al Benson III, MD, FACP is a scientific advisor and has received research support from Amgen Inc., Bristol-Myers Squibb, Genentech, Inc., Imclone Systems Inc., MDS Nordion, Wyeth, Pfizer Inc., Roche Laboratories Inc., sanofi-aventis, and Taiho Pharmaceutical Co., Ltd.

Gary Rice, RPh, MS, MBA has nothing to disclose.


*Content will include non-FDA-approved uses.

Disclaimer
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Related Items
New Directions in the Treatment and Symptom Management of Multiple Sclerosis – Part 2
Samuel F. Hunter, MD, PhD, Gary M. Owens, MD
Interactive Learning published on June 13, 2013
Myelofibrosis and Multiple Myeloma: Strategies for Effective Decision-Making
Martha L. Arellano, MD, Jonathan L. Kaufman, MD , James T. Kenney Jr, RPh, MBA, Gary M. Owens, MD
Supplements published on July 31, 2012
Emerging Treatments and Evolving Strategies for the Cost-Effective Management of Myelofibrosis
Gary M. Owens, MD, Alfonso Quintas-Cardama, MD , Atheer A. Kaddis, PharmD
Interactive Learning published on July 15, 2012
Optimizing New and Emerging Therapies for Treatment and Symptom Management of Multiple Sclerosis in Managed Care
Gary M. Owens, MD, Bruce L. Hughes, MD , Sonya J. Lewis, RPh, MBA
Supplements published on August 2, 2011
Evolving Role of Biologics: A Payer’s and Provider’s Perspective
Gary Rice, RPh, MS, MBA
Supplements published on April 29, 2011
Wellness and Prevention in Chronic Disease Consensus Statement
Gary M. Owens, MD, Nirav R. Shah, MD, MPH, FACP, Michael McLean, RPh, MPA, Kip Piper, MA, FACHE, Doug Burgoyne, PharmD, John Fox, MD, Stacie Heller, Wayne M. Lednar, MD, PhD, Lynne Rothney-Kozlak, Scott R. Taylor, RPh, MBA, F. Randy Vogenberg, RPh, PhD
Supplements published on September 30, 2010
Highlights from ASCO 2010: An Update for Payers and Providers on Chronic Myelogenous Leukemia
Gary M. Owens, MD, Michael Mauro, MD
Supplements published on September 15, 2010
Health System/Regional Variations in the Delivery of Care for Multiple Myeloma
Gary M. Owens, MD, Jatin Shah, MD, Rusty Crawford, RPh, BCOP, Sin (Masha) Lam, PharmD, BCOP, Stephanie S. Minich, PharmD, BCOP
Supplements published on March 30, 2010
ASCO 2009 Highlights on Breast Cancer: A Payer's and Pharmacist's Perspective
Gary M. Owens, MD
Supplements published on September 15, 2009
NCCN Updated Guidelines for Breast Cancer: A Payer's Perspective
Gary Rice, RPh, MS, MBA
Supplements published on August 14, 2009
Last modified: March 24, 2014